ViroGates AS (FRA:EP2) EPS without NRI: €-0.16 (TTM As of Mar. 2026)


FRA:EP2 ViroGates AS FRA:EP2
44 GF Score
Price €1.45
GF Value €0.90
! 2 Warning Signs
View Full Analysis

What is ViroGates AS EPS without NRI?

ViroGates AS FRA:EP2 +2.84% 44 EPS without NRI is €-0.16 as of Mar. 2026. GuruFocus rates FRA:EP2 with a GF Score™ of 44/100 and a GF Value™ of €0.90. The stock has 2 warning signs investors should review. Among 666 Medical Devices & Instruments companies, ViroGates AS ranks better than 70.42% on this metric.

ViroGates AS's earnings per share without non-recurring items for the three months ended in Mar. 2026 was €-0.04. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.16.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 23.60% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 21.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for ViroGates AS's EPS without NRI or its related term are showing as below:

FRA:EP2' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.7   Med: 9.3   Max: 23.6
Current: 23.6

During the past 10 years, ViroGates AS's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 23.60% per year. The lowest was -48.70% per year. And the median was 9.30% per year.

FRA:EP2's 3-Year EPS without NRI Growth Rate is ranked better than
70.42% of 666 companies
in the Medical Devices & Instruments industry
Industry Median: 8.15 vs FRA:EP2: 23.60

ViroGates AS's EPS (Diluted) for the three months ended in Mar. 2026 was €-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.16.

ViroGates AS's EPS (Basic) for the three months ended in Mar. 2026 was €-0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €-0.16.


ViroGates AS  (FRA:EP2) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


ViroGates AS EPS without NRI Related Terms


ViroGates AS EPS without NRI Historical Data

* Premium members only.

The historical data trend for ViroGates AS's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ViroGates AS EPS without NRI Chart

ViroGates AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.58 -0.40 -0.47 -0.29 -0.18

ViroGates AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.05 -0.06 -0.03 -0.04 -0.04

FRA:EP2 vs ABT, SYK, MDT: EPS without NRI Comparison

For the Medical Devices subindustry, ViroGates AS's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViroGates AS PE Ratio without NRI vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ViroGates AS's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where ViroGates AS's PE Ratio without NRI falls into.


FRA:EP2
44GF Score
ViroGates AS FRA:EP2
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ViroGates AS EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of €-0.16 mean?
ViroGates AS (FRA:EP2) has a EPS without NRI of €-0.16 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on ViroGates AS and its competitors. According to the industry distribution chart, ViroGates AS ranks #197 out of 666 companies in the Medical Devices & Instruments industry, placing it in the top 29.6%.
Is ViroGates AS's EPS without NRI too high?
ViroGates AS's current EPS without NRI is €-0.16. Based on the distribution chart, ViroGates AS ranks #197 out of 666 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, ViroGates AS has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does ViroGates AS's EPS without NRI compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, ViroGates AS ranks #197 out of 666 companies for EPS without NRI. This puts ViroGates AS in the upper half of its industry. The industry median EPS without NRI is 8.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Medical Devices & Instruments company?
The median EPS without NRI among Medical Devices & Instruments companies is 8.15, based on 666 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on ViroGates AS and its competitors. For the Medical Devices & Instruments industry, the median EPS without NRI is 8.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ViroGates AS's current EPS without NRI is €-0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ViroGates AS stock overvalued right now?
ViroGates AS (FRA:EP2) has a current EPS without NRI of €-0.16. The stock's GF Value™ is €0.90, compared to a current price of €1.45 — trading 61.1% above its estimated fair value. The current EPS without NRI is €-0.16. ViroGates AS's overall GF Score™ is 44/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For ViroGates AS (FRA:EP2), the current EPS without NRI is €-0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ViroGates AS (FRA:EP2) Overvalued in 2026?

Based on GuruFocus' analysis, ViroGates AS stock appears to be overvalued. The current stock price of €1.45 is trading 61.1% above its estimated GF Value™ of €0.90.

Key valuation signals for FRA:EP2:

  • EPS without NRI: €-0.16
  • GF Value™: €0.90 vs. price of €1.45 (61.1% above fair value)
  • GF Score™: 44/100 with 2 warning signs

No single metric tells the full story. See the FRA:EP2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ViroGates AS Business Description

Other Exchanges VIRO:Denmark
Address Banevaenget 13, Birkerod, DNK, 3460
ViroGates AS is an international medical technology company that develops and markets blood tests to measure chronic inflammation at health clinics and hospitals. The company markets its blood test products under the suPARnostic brand. Its product portfolio comprises suPARnostic TurbiLatex, suPARnostic Quick Triage, and suPARnostic Auto Flex ELISA kit. These products are mainly used to measure the suPAR (soluble urokinase Plasminogen Activator Receptor) protein in the bloodstream.
44GF Score

Get the complete analysis for FRA:EP2

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.45
Price
€0.90
GF Value